The Academic Research Consortium Governance Charter  by Krucoff, Mitchell W. et al.
AD
S
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 5 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 3 . 0 0 8ACC INTERVENTIONAL SCIENTIFIC COUNCIL: NEWS AND VIEWS
The Academic Research Consortium
Governance Charter
Mitchell W. Krucoff, MD,* Roxana Mehran, MD,† Gerrit-Anne van Es, PHD,‡
shley B. Boam, MSBE,§ Donald E. Cutlip, MD
urham, North Carolina; New York, New York; Rotterdam, the Netherlands;
ilver Spring, Maryland; and Boston, MassachusettsEvaluation of new medical devices and demonstra-
tion of their conformity to essential principles of
safety and effectiveness frequently require clinical
trials in human subjects. For many cardiovascular
devices, in particular implantable or invasive de-
vices, ethical, clinical, and logistical constraints must
be integrated into the balance of how best to encour-
age innovation and brisk access to better therapies
with potential safety concerns and their evaluation.
As device manufacturing and adoption progress
throughout the total product life cycle, the ability
to aggregate data across individual clinical trials,
patient subgroups, or device models adds critical
knowledge, in particular with regard to safety. One
of the most fundamental barriers to meaningful
data aggregation is the use of different nomencla-
ture and definitions of key descriptors and end-
points from 1 trial to another, or from 1 manufac-
turer to another. Thus, the eventuation of robust,
practical consensus definitions and nomenclature
represents a manageable and important advance in
the quality, speed, and cost of research and devel-
opment pathways for new devices.
Controversies around optimal definitions for clinical
safety and effectiveness outcomes frequently result from
variations in sensitivity and specificity limitations related
to the evidence available in living human subjects.
Consensus definitions do not resolve such controversy,
or necessarily represent definitions that are somehow
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relationships to disclose.more “right or wrong” than may be available using other
options. The consistent use of well-considered con-
sensus definitions throughout the life cycle of a
medical device, however, has unique value to scien-
tific, clinical, regulatory, and industry stakeholders
and most importantly, to protection of the public
health, well beyond the limitations of relative degrees
of accuracy or inaccuracy.
Definitions per se are not self-sufficient, but are
dependent on how they are used. Thus, optimal con-
sensus definitions and nomenclature may be crafted
differently for different purposes. Professional societies or
expert panels developing consensus definitions to sup-
port practice guidelines, for instance, may prefer differ-
ent constructs of evidence than a clinical events com-
mittee or a data and safety monitoring committee might
require for a clinical trial.
The purpose of the Academic Research Consortium
(ARC) is to create a dynamic, open-ended, transparent,
collaborative forum across stakeholders, whose objective
is to develop consensus definitions and nomenclature
and related processes, optimized for application in piv-
otal clinical trials of specific classes of new medical
devices, and to disseminate such definitions and recom-
mended processes into the public domain.
The ARC was founded in 2006 as an informal
collaboration between 4 academic research orga-
nizations—the Harvard Clinical Research Insti-
tute (HCRI), Cardialysis, the Cardiovascular Re-
search Foundation (CRF), and the Duke Clinical
Research Institute (DCRI), with advisory participa-
tion of the U.S. Food and Drug Administration
(FDA). Thought leaders from the medical industry
were centrally involved as nonvoting stakeholders.
The group first focused on key definitions for appli-
cation to coronary stent studies, conducting a series of
think tank meetings and publishing the consensus
document in the peer review literature in 2007.
Currently, 4 additional ARC efforts are in progress
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596in the areas of key definitions for percutaneous valve studies
(valve ARC, or VARC); for characterization of bleeding
complications in cardiovascular trials (bleeding ARC, or
BARC); and for peripheral intervention (peripheral ARC,
or PARC), and for atrial fibrillation (AF-ARC).
Mission Statement
The ARC’s mission is to promote informed and collabora-
tive dialogue across stakeholders supporting the develop-
ment of consensus definitions and nomenclature for tar-
geted areas of new medical device development, and to
disseminate such definitions in the public domain.
Organizational Composition and Membership
The ARC will comprise a steering group and an open-
ended array of focused project teams. The ARC represents
a consensual alliance of like-minded professionals, or con-
sortium, not a contracted or legally bound entity.
ARC Steering Group. The ARC steering group comprises
appointees from each of the 4 founding research organiza-
tions in conjunction with advisory liaison representation
from the U.S. FDA. The steering group will function to:
• Coordinate ARC operations in accordance with this charter;
• Review and modify this charter as necessary over time;
• Review and define key focus areas for ARC focused
project teams;
• Coordinate and facilitate the planning and content of
ARC programs;
• Develop and facilitate ARC project teams; and
• Facilitate milestones and timelines for deliverables.
The Steering Group:
1. Gerrit-Anne van Es (Cardialysis), e-mail: gaves@cardialysis.nl
2. Donald E. Cutlip (HCRI), e-mail: don.cutlip@hcri.
harvard.edu
. Roxana Mehran (CRF), e-mail: roxana.mehran@mssm.edu
. Mitchell W. Krucoff (DCRI), e-mail: kruco001@mc.duke.edu
. Ashley Boam (FDA), e-mail: ashley.boam@fda.hhs.gov
ARC focused project teams. Focused project teams will be
eveloped and tasked to address specified areas of medical device
evelopment warranting consensus definitions useful for pivotal
linical trial purposes. Specifically, focused project teams will:
Include 2 project team leaders, at least 1 of whom is affiliated
with 1 of the 4 founding ARC research organizations;
Endeavor to include high-level expertise from all stake-
holders relevant to the specific device area of focus;
Conduct think tanks, teleconferences, and e-mail inter-
actions sufficient to develop consensus definitions; and
Coordinate and complete the process sufficiently to dissem-
inate such definitions in the public domain through publi-
cation in the peer-reviewed literature.Membership. Membership in ARC is voluntary, without
dues or contractual obligation. Individuals constituting the
ARC steering group are determined by the parent research
organizations; the FDA liaison to the ARC steering group
is determined by FDA. Members of the ARC focused project
teams are determined through participation in the project
team functions listed in the previous text, and as coordi-
nated by the 2 project team leaders.
Professional societies and other public domain organizations
with overlapping interest areas to ARC programs provide a unique
locus of expertise in definitions of key terminology used in
guidelines and quality registry databases. Interactions between
ARC and professional societies are encouraged through the
identification by such societies of individuals to serve as liaisons
between ARC efforts on behalf of the society. Processes for
naming such liaisons reside within the professional society. ARC
recognition of such liaison roles is provided through the focused
project team leaders, similar to other voluntary membership roles.
Processes. The ARC steering group will conduct meetings,
either face to face or via teleconferencing, at least quarterly
per annum. Priorities, operations, project selection, finance,
and other ad hoc items will be reviewed.
Planning for specific focused project meetings, including
meeting location, timing, agenda, and documentation, will
be coordinated by the project teams and team leaders, with
facilitative oversight from the steering group.
RESOURCES. Both in-kind and financial resources will be utilized on
an ad hoc basis. All financial transactions, sources, budgets, and
use will be fully transparent. In specific settings, resources may also
be developed through federal or professional society funding or
grants. No personal revenues, honoraria, or other financial
incentives or rewards will be provided in conjunction with
ARC activities or deliverables.
ANNUAL MEETING. An annual public meeting will be held and
ill serve the following primary purposes:
Provide updates and review of existing focused projects;
Orchestrate dialogue identifying key areas and priorities
for future focused project efforts; and
Consider the need for changes to this charter.
FOCUSED PROJECT MEETINGS. Focused project meetings will serve to
ring stakeholders together in open dialogue supporting the
ventuation of consensus definitions for focused medical device
opical areas.
FOCUSED PROJECT MANUSCRIPTS. These manuscripts will provide
he mechanism for public dissemination of consensus defi-
itions for focused medical device topical areas.
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